Applies to Medicaid plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
OSA indication — initial approval
All of:
- Patient is 18 years of age or older
- Diagnosis of moderate to severe obstructive sleep apnea (AHI ≥ 15)
- Obesity (BMI ≥ 30 kg/m²)
- No diagnosis of diabetes
- Patient has been counseled to continue a reduced-calorie diet and increased physical activity
- Not taking this medication in combination with another GLP-1 agonist
Documentation to bring
- Documentation of patient age ≥ 18 years
- Documentation of moderate to severe obstructive sleep apnea diagnosis (AHI ≥ 15)
- Documentation of obesity (BMI ≥ 30 kg/m²)
- Documentation confirming no diagnosis of diabetes
- Documentation that patient has been counseled on reduced-calorie diet and increased physical activity
- Confirmation that patient is not taking medication in combination with another GLP-1 agonist
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
Not covered when
- Patients with a diagnosis of diabetes are excluded from OSA indication
- Combination use with another GLP-1 agonist is excluded
- Stable therapy pathway does not apply to OSA indication
Policy note: The document explicitly states 'Stable therapy does not apply' for the OSA indication. The standard prior treatment trial requirement (failed 30-day trials with two preferred agents) does not appear to be applied to the OSA indication — this indication has its own specific criteria set out separately. The step-therapy / prior treatment trial language appears to apply to the diabetes indication for the class; OSA criteria are specified independently.
Policy effective August 15, 2025 · verified June 3, 2026 · source: Alabama Medicaid Medicaid prior authorization policy · View policy document (PDF)